How can you achieve "Tests that take hours as opposed to days ... will have a positive patient impact."

Scientific Director of the Esoteric Testing/R&D Department
Tampa General Hospital

Expand your lab’s molecular testing potential

- **Workflow efficiency** for timely patient management
- Diagnostic **speed and accuracy** to aid in fast, appropriate treatment
- Testing **versatility** for a wide range of patients

Visit [moleculardiagnostics.bd.com](http://moleculardiagnostics.bd.com) to find out how
Elevate the standard of care
Introducing the BD MAX™ Vaginal Panel

The first microbiome-based, polymerase chain reaction (PCR) assay that directly detects the 3 most common infectious causes of vaginitis¹

- Bacterial vaginosis, vulvovaginal candidiasis, and Trichomonas vaginalis¹
- Maximize efficiency with 1 collection, 1 test for the 3 most common infectious causes of vaginitis
- Supports antimicrobial resistance initiatives by reporting Candida krusei and C. glabrata

Why change?

Traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.² The BD MAX™ Vaginal Panel provides more complete, accurate detection,¹ to help more patients.

Significant prevalence.

Severe complications.

Why now?

Health risks include

- Preterm or low birth-weight babies
- Late-term miscarriage
- Increased risk of sexually transmitted infections such as HIV and pelvic inflammatory disease¹

A need for improved testing

Clinical diagnosis and traditional diagnostic techniques tend to be subjective with variable sensitivity and specificity.¹

40% of women with vaginitis leave an initial medical visit undiagnosed²

This potentially leads to:

- Continued symptoms
- Repeat visits
- Inappropriate treatment
- Poor antimicrobial stewardship
- Unnecessary associated healthcare system costs²,³,⁵

Overall performance compared to patient infection status¹

<table>
<thead>
<tr>
<th></th>
<th>Clinician- Collected</th>
<th>Self- Collected</th>
<th>Contrived Samples²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sens *</td>
<td>Spec **</td>
<td>Sens</td>
</tr>
<tr>
<td>Bacterial Vaginosis</td>
<td>90.5%</td>
<td>85.7%</td>
<td>90.7%</td>
</tr>
<tr>
<td>Candida group ¹</td>
<td>90.9%</td>
<td>94.1%</td>
<td>92.2%</td>
</tr>
<tr>
<td>Candida glabrata ¹</td>
<td>75.9%</td>
<td>99.7%</td>
<td>86.7%</td>
</tr>
<tr>
<td>Candida krusei ¹</td>
<td>No Data</td>
<td>99.8%</td>
<td>No Data</td>
</tr>
<tr>
<td>Trichomonas vaginalis ¹</td>
<td>93.1%</td>
<td>99.3%</td>
<td>93.2%</td>
</tr>
</tbody>
</table>

* Sensitivity **Specificity
¹ Candida group includes C. albicans, C. dubliniensis, C. parapsilosis and/or C. tropicalis
² Positive Percent Agreement
³ Negative Percent Agreement
⁴ Out of 7 C. glabrata false negative results, 6 showed chromagar results consistent with low C. glabrata load (1+ to 2+ growth level) and 1 showed chromagar result consistent with high C. glabrata load (3+ growth level).
⁵ No C. krusei positive specimens were identified in the study by the Reference Method.
⁶ 9 false-negative results were recorded. Of those, 7 were found negative with an FDA-cleared molecular method.
⁷ For rare analytes, an evaluation of contrived specimens was performed to supplement data collected in the study. Half of the positive contrived specimens were at ≥1 and <2 LoD.

Why BD?

Accurate treatment begins with an accurate diagnosis. BD MAX Vaginal Panel is the first FDA-authorized, microbiome-based assay that detects the 3 most common infectious causes of vaginitis,³ with the efficiency of 1 swab. Consistent, accurate results that surpass traditional methods for vaginitis detection.¹


BD, Sparks, MD 21152-0999 USA
800.638.8663

bd.com

© 2018 BD. BD, the BD Logo and BD MAX are trademarks of Becton, Dickinson and Company.